Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
rhGH Effects on Health Outcomes Reported in Controlled Trials
Health outcomes of interest include hospitalization rate, antibiotic use, pulmonary exacerbations, HRQoL, bone consequences and mortality. In studies of rhGH treatment of patients with CF, the hospitalization rate was reduced when compared with controls by 1.62 per year. There is insufficient evidence about antibiotic use, pulmonary exacerbations, and HRQoL to estimate an effect of treatment. Bone consequences and mortality were not reported in any rhGH trial.
Keywords: hospitalization | rate | pulmonary | exacerbation | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.